+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A novel TLR3 inhibitor encoded by African swine fever virus (ASFV)



A novel TLR3 inhibitor encoded by African swine fever virus (ASFV)



Archives of Virology 156(4): 597-609



African swine fever virus (ASFV) encodes proteins that manipulate important host antiviral mechanisms. Bioinformatic analysis of the ASFV genome revealed ORF I329L, a gene without any previous functional characterization as a possible inhibitor of TLR signaling. We demonstrate that ORF I329L encodes a highly glycosylated protein expressed in the cell membrane and on its surface. I329L also inhibited dsRNA-stimulated activation of NFκB and IRF3, two key players in innate immunity. Consistent with this, expression of I329L protein also inhibited the activation of interferon-β and CCL5. Finally, overexpression of TRIF reversed I329L-mediated inhibition of both NFκB and IRF3 activation. Our results suggest that TRIF, a key MyD88-independent adaptor molecule, is a possible target of this viral host modulation gene. The demonstration of an ASFV host evasion molecule inhibiting TLR responses is consistent with the ability of this virus to infect vertebrate and invertebrate hosts, both of which deploy innate immunity controlled by conserved TLR systems.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051190396

Download citation: RISBibTeXText

PMID: 21203785

DOI: 10.1007/s00705-010-0894-7


Related references

Virus-specific CTL in SLA-inbred swine recovered from experimental African swine fever virus (ASFV) infection. Annals of the New York Academy of Sciences 532: 462-464, 1988

The low-virulent African swine fever virus (ASFV/NH/P68) induces enhanced expression and production of relevant regulatory cytokines (IFNalpha, TNFalpha and IL12p40) on porcine macrophages in comparison to the highly virulent ASFV/L60. Archives of Virology 153(10): 1845-1854, 2008

Swine monocytes macrophages can be stimulated by the murine macrophage growth factor csf 1 in vitro use in a virus cell model for investigating african swine fever virus asfv. Abstracts of the Annual Meeting of the American Society for Microbiology 89: 379, 1989

Structure of African swine fever virus (ASFV). Hog Cholera: sical Swine Fever and African Swine Fever, 543-554, 1977

Some considerations on African swine fever virus (ASFV) infection. Revista Portuguesa de Ciencias Veterinarias 93(525): 3-23, 1998

The non-haemadsorbing African swine fever virus isolate ASFV. Journal of general virology 82(3): 513-523, 2001

Specific resistance to the african swine fever virus asfv. Revista Portuguesa de Ciencias Veterinarias 86(498): 76-82, 85-88, 1991

Antibody studies in animals infected with African swine fever virus (ASFV). Fedn Proc 26: 2, 482 p, 1967

Porcine immune responses to African swine fever virus (ASFV) infection. Veterinary Immunology and Immunopathology 43(1/3): 99-106, 1994

Molecular characterization of the non-haemadsorbing African swine fever virus isolate (ASFV/NH/P68). Revista Portuguesa de Ciencias Veterinarias 90(515): 120-130, 1995

A Mathematical Model that Simulates Control Options for African Swine Fever Virus (ASFV). Plos one 11(7): E0158658, 2016

The non-haemadsorbing African swine fever virus isolate ASFV/NH/P68 provides a model for defining the protective anti-virus immune response. Journal of General Virology 82(Pt 3): 513-523, 2001

In vitro inhibition of the replication of haemorrhagic septicaemia virus (VHSV) and African swine fever virus (ASFV) by extracts from marine microalgae. Antiviral Research 44(1): 67-73, 1999

Survival of African swine fever virus (ASFV) in various traditional Italian dry-cured meat products. Preventive Veterinary Medicine 162: 126-130, 2019

African swine fever virus (ASFV) protection mediated by NH/P68 and NH/P68 recombinant live-attenuated viruses. Vaccine 36(19): 2694-2704, 2018